Iambic closed a $100 million financing round to advance clinical trials of cancer candidates discovered using its AI platform; the company recently presented breast‑cancer data at the European Society for Medical Oncology (ESMO). The raise will fund IND‑enabling work and early‑phase studies while validating AI‑first discovery models in oncology. Investors cited the company’s translational data and the growing investor appetite for AI‑driven drug discovery as rationale for the large round, underscoring increased capital flow into computational drug developers.